The conditional approval of fanregratinib is supported by pivotal phase 2 data showing a 42.5% objective response rate in pretreated FGFR2-altered intrahepatic cholangiocarcinoma.
|Videos|May 26, 2011
Donna Berry on the Future of Oncology Nursing
Author(s)Donna L. Berry, PhD, RN
Donna Berry from the Phyllis F. Cantor Center at the Dana-Farber Cancer Institute on the Future of Oncology Nursing
Advertisement
Donna Berry, PhD, RN, AOCN®, FAAN, from the Phyllis F. Cantor Center at the Dana-Farber Cancer Institute describes her thoughts on the future of oncology nursing; specifically eliminating the science and practice gap.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance
2
Arlo-Cel Meets ORR End Point in BCMA-Pretreated, Quadruple-Class Exposed R/R Myeloma
3
Camidge and Singhi Highlight the Lung Cancer Abstracts to Watch at WCLC 2026
4
Frontline Mipletamig Triplet Drives Clinical Benefit in TP53-Mutated AML
5